Mesoblast Stock Earnings Reports

Mesoblast reported strong FY2025 operational and financial progress driven by the commercial launch of Ryoncil, the first and only FDA-approved mesenchymal stromal cell (MSC) therapy in the U.S. Key financials: product revenue from cell therapy products was $17.2 million (up 191% year-over-year), including $13.2 million in gross sales in the quarter of launch and $11.3 million net sales after a 14.6% gross-to-net adjustment; gross margin on product sales was ~90%; net operating cash spend was ~$50 million; cash on hand at June 30, 2025 was $162 million (AUD 247 million). Commercial progress: Ryoncil became commercially available March 28, 2025; 32 transplant centers onboarded to date with a goal to reach the top 45 centers accounting for ~80% of pediatric bone marrow transplants; payer coverage now includes >250 million lives and nationwide Medicaid coverage effective July 1; a specific J-code for Ryoncil is effective Oct 1. Clinical and pipeline updates: Ryoncil is approved for pediatric steroid-refractory acute GvHD with strong Phase III data (70% day-28 response in a severe cohort) and durable long-term survival signals; Mesoblast plans a pivotal adult acute GvHD trial (adding Ryoncil on top of ruxolitinib) to start this quarter in partnership with the NIH-funded BMT-CTN, aiming to expand the label to an addressable adult market roughly three times the pediatric population. Ryoncil label extension opportunities also include inflammatory bowel disease (plans to initiate a pivotal study for medically-refractory colitis). Second-generation rexlemestrocel-L (Revascor) continues toward an accelerated approval pathway in chronic heart failure targeting high-risk ischemic/inflammatory patients; Mesoblast has aligned with FDA on chemistry, manufacturing controls and a confirmatory trial design. A confirmatory Phase III trial in chronic low back pain (single injection) is actively enrolling (~40 U.S. sites) with expected last-patient-in by end of year or Q1 next year and a 12-month primary endpoint. Corporate priorities for the next 12 months: commence adult GvHD registration study, initiate inflammatory colitis study, prepare accelerated approval filing for Revascor, and complete enrollment of the low back pain confirmatory trial. Risks/notes: increased SG&A from commercial build, non-cash revaluation charges (contingent consideration, warrants) impacted reported results; forecasting remains early given only one quarter of launch sales reported.